ZS Pharma

Committed to Advancing Patient Care

  • Developing New Therapies to Improve the Treatment of HyperkalemiaThe core of our R&D program is to develop safe and efficacious treatments for patients with serious conditions using a novel selective ion-trap technology
  • Partnering with Clinicians to Advance Hyperkalemia Treatment ZS Pharma is committed to improving patient outcomes by developing novel therapies to treat potentially life-threatening conditions, such as hyperkalemia
  • Our Commitment to the PatientZS Pharma is committed to improving patient outcomes and care by developing novel therapies to treat and manage Hyperkalemia
1 Developing New Therapies to Improve the Treatment of Hyperkalemia2 Partnering with Clinicians to Advance Hyperkalemia Treatment 3 Our Commitment to the Patient4

Our Commitment

ZS Pharma is a biopharmaceutical company committed to the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. Our initial focus is on the development of ZS-9, our product candidate in Phase 3 development for the treatment of hyperkalemia, a potentially life-threatening condition characterized by abnormally high levels of potassium in the blood.

We are advancing ZS-9 through clinical development with the goal of obtaining approval for the treatment of acute and chronic hyperkalemia, regardless of the underlying disease state.

Stay in the Know

Keep up to date with the latest ZS Pharma News and Updates

Sign Up

 

Recent News

November 21, 2014

ZS Pharma Announces Publication of Results from Phase 3 Study of ZS-9 in Patients with Hyperkalemia in the New England Journal of Medicine

Download PDF

November 17, 2014

ZS Pharma Presents Positive Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia, at the American Heart Association Scientific Meeting and Announces Simultaneous Publication of Results in JAMA

Download PDF

November 10, 2014

ZS Pharma Reports Third Quarter 2014 Financial Results and Provides ZS-9 Program Update

Download PDF
X

Keep up to date with the latest ZS Pharma News and Updates